Floatz logo

Dexasone

Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

58 Active assets in the Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-Vincristine
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
Adriamycin
Falo, Louis, MD
Phase 4BBB
Nivestim
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Dexasone is also rated in:

chemotherapy-induced toxicityActive
A
Indicative · Phase 4
82 / 100
View asset →
adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →